Clinical aspects, laboratory investigation, and treatment of hyperthyroidism and hypothyroidism are reviewed in light of recent information. Special circumstances, such as hyperthyroidism during pregnancy, Graves ophthalmopathy, iodine-induced hyperthyroidism, and subclinical hypothyroidism, are also considered.

Hyperthyroidism and hypothyroidism are common disorders, especially in women. In the 20-year follow-up of the original Whickham survey, which involved several thousand randomly selected adults 18 years or older at enrollment, 0.8 per 1000 surviving women per year developed hyperthyroidism and 3.5 per 1000 per year developed spontaneous hypothyroidism. In 1995, the American Thyroid Association published guidelines for the management of these disorders. In this article, I provide an update of their management in light of more recent information.

HYPERTHYROIDISM

Although the terms hyperthyroidism and thyrotoxicosis are frequently used interchangeably, in the strictest sense hyperthyroidism refers to hyperfunction of the thyroid gland, whereas thyrotoxicosis refers to any state characterized by thyroid hormone excess, including ingestion of excess thyroid hormone and thyroiditis. This article, therefore, will be principally concerned with the management of hyperthyroidism caused by Graves disease or associated with toxic nodular goiter.

Clinical Considerations

A diagnosis of hyperthyroidism is suggested by the presence of a constellation of symptoms and signs. In patients older than 70 years, however, the classic clinical manifestations may be lacking and goiter may be absent. Instead, anorexia with wasting, atrial fibrillation, or congestive heart failure may be the predominant manifestations. Furthermore, the cause of hyperthyroidism will differ between young and elderly patients. In young patients Graves disease is almost always the cause, whereas in elderly patients toxic nodular goiter is also a common cause.

Laboratory Investigation

Measurement of serum thyrotropin, using at least a second-generation assay (detection limit, approximately 0.05 mIU/L), is the most sensitive test for screening for hyperthyroidism, a normal result virtually excluding hyperthyroidism, except in the rare instance where it is due to thyrotropin hypersecretion. An undetectable value is the hallmark of hyperthyroidism, but a low or sometimes an undetectable value using a second-generation assay may occur in some healthy elderly patients, in patients with nonthyroid illness, or in patients taking a glucocorticoid or dopamine hydrochloride. In these circumstances, a third-generation assay (detection limit, approximately 0.005 mIU/L) will afford the necessary distinction, because in hyperthyroidism serum thyrotropin is still undetectable, whereas in the other conditions thyrotropin is almost always detectable, albeit low. Confirmation is sought in measurement of serum free...
thyroxine (FT<sub>4</sub>). Occasionally, measurement of serum free triiodothyronine (FT<sub>3</sub>) will be necessary in a patient with clinical manifestations of hyperthyroidism and an undetectable serum thyrotropin and normal serum FT<sub>4</sub> levels, defining the entity of triiodothyronine toxicosis.

In a patient with overt ophthalmopathy, no additional testing is required, because the patient certainly has Graves disease. However, in a woman of child-bearing age, it is essential to determine whether she is pregnant, because this will clearly influence the subsequent management (vide infra). In a patient without ophthalmopathy, measurement of thyroid radiodine (<sup>131</sup>I) uptake should be performed to establish the cause of thyrotoxicosis, ie, whether it is due to hyperthyroidism, in which case the uptake will be high, or to some other condition where thyroid hyperfunction is lacking, such as thyroid hormone ingestion or thyroiditis, in which case the uptake will be low. A <sup>131</sup>I scintiscan may be helpful in a patient with a nodular goiter, because it will serve to define the functional characteristics of the gland.

**Treatment**

Hyperthyroidism may be treated with antithyroid drugs, <sup>131</sup>I, or subtotal thyroidectomy, the type of treatment being determined by the form of hyperthyroidism, the age of the patient, the size of the goiter, and the presence of coexisting conditions.

**Antithyroid Drugs.** Methimazole and propylthiouracil, the 2 drugs available in the United States, are thioamides that are concentrated in thyroid tissue and inhibit hormone biosynthesis. In the United Kingdom and Europe, carbimazole is the commonly used drug; it is virtually completely converted to methimazole in vivo. In large doses, propylthiouracil also inhibits the peripheral tissue conversion of thyroxine to triiodothyronine. Methimazole is used in preference to propylthiouracil, because it has a longer inhibitory effect on glandular hormone synthesis and can therefore be taken as a single daily dose, improving compliance. Moreover, in doses up to 30 mg/d, methimazole may carry a lower risk of agranulocytosis.

Treatment is usually initiated with 30 mg of methimazole daily or 100 mg of propylthiouracil 3 times daily. The patient should be alerted to the major, albeit rare (<1%), adverse effects of these drugs, including agranulocytosis, liver disease, and a lupuslike syndrome that tend to occur within the first several months of therapy. Baseline laboratory data should include a leukocyte count and liver function tests, and monitoring of the leukocyte count may predict agranulocytosis. The patient should be instructed to notify the physician immediately if symptoms suggesting one of these adverse reactions appear. Withdrawal of the drug will result in resolution of the adverse reaction, but both antithyroid drugs are contraindicated thereafter, and the patient will have to be treated with <sup>131</sup>I or surgery. With minor adverse reactions, such as pruritus, the patient can be switched to the alternate agent.

After treatment has been initiated, the patient should be followed up at approximately monthly intervals and the antithyroid drug dose reduced to a maintenance dose as a euthyroid state is approached. The speed with which this is attained is determined by the severity of disease, goiter size, and dose of antithyroid drug. During this interim period, a β-adrenergic receptor blocking agent, such as propranolol hydrochloride, may be used to control the hyperadrenergic manifestations, such as tremor, anxiety, and palpitations, if these are troublesome, provided the patient does not have obstructive pulmonary disease or other contraindications to its use. Measurement of serum FT<sub>4</sub> rather than thyrotropin should be used to monitor treatment, since serum thyrotropin may remain undetectable for many months after a euthyroid state is restored. Thereafter, the patient should be seen every 3 months if long-term therapy is planned.

Long-term antithyroid drug therapy is only appropriate for Graves hyperthyroidism, since this disorder has the potential to enter a spontaneous remission. It is generally considered the treatment of choice for young patients with a small goiter or patients with active ophthalmopathy (vide infra). Antithyroid drugs are not indicated as long-term therapy in toxic nodular goiter, since hyperthyroidism does not remit. The likelihood of a long-term remission is positively influenced by the duration of antithyroid drug therapy, and a duration of 1 to 2 years is recommended, with reported remission rates ranging from 37% to 70%. Initial work had suggested that adding levothyroxine sodium to long-term antithyroid drug therapy in patients with Graves disease resulted in a greater likelihood of remission when the antithyroid drug was withdrawn. The rationale for this approach was that the antithyroid drugs might also exert an immunosuppressive action, and combination therapy permitted the use of a higher dose of antithyroid drug. However, several more recent studies<sup>6-9</sup> have failed to confirm these earlier findings. There are no absolute predictors of outcome following withdrawal of therapy, but certain features, such as a small goiter, favor remission, whereas others, such as persistence of undetectable thyrotropin or high thyrotropin receptor antibody titer, favor relapse.<sup>6</sup>

Following withdrawal of long-term therapy, the patient should continue to be seen every 3 months for the first year, since relapse is most likely within this period. Thereafter, the patient should be seen annually, since relapse may occur in later years. Should relapse occur, the patient should be treated with <sup>131</sup>I or subtotal thyroidectomy, although antithyroid drug therapy could be reintstituted if the patient wishes to avoid ablative therapy.

**Radiiodine.**<sup>131</sup>I is the treatment of choice for patients with Graves hyperthyroidism who relapse after long-term antithyroid drug therapy, for patients with severe thyrocardiac disease, for most patients with toxic multinodular or uniodular goiter, and for patients with a major adverse reaction to antithyroid drugs. <sup>131</sup>I therapy is absolutely con-
of131I through a putative radiopro-
cil, but perhaps not methimazole,
Pretreatment with propylthioura-
required to achieve a euthyroid state.
The dose of 131I used to treat
 Graves hyperthyroidism ranges from
185 to 555 MBq (5-15 mCi), de-
ning on the size of the goiter and the
magnitude of uptake of an an-
tecedent tracer dose of 131I. With
toxic nodular goiter, larger doses are
required to achieve a euthyroid state.
Pretreatment with propylthioura-
cil, but perhaps not methimazole,
may reduce the one-dose cure rate
of 131I through a putative radioprotective effect.12,13 Accordingly, meth-
imazole should only be used before
131I treatment in patients with se-
vere hyperthyroidism or a very large
goiter to forestall exacerbation of hy-
perthyroidism as a result of the tran-
sient radiation thyroiditis. In these
circumstances, the antithyroid drug
is given to restore euthyroidism and
then stopped 3 to 5 days before the
administration of 131I.

In more than 80% of patients,
hyperthyroidism will be cured and
the goiter will decrease with a single
dose of 131I. Since it may take sev-
eral months for euthyroidism to be
restored, patients with severe hy-
perthyroidism may require treat-
ment with an antithyroid drug or a
β-adrenergic receptor blocking agent
during this interim period. Women
of child-bearing age should be ad-
vised to postpone conception for at
least 6 months after treatment with
131I.

Permanent hypothyroidism is
the major complication of 131I
therapy, its prevalence at 1 year be-
ing determined by the dose given.
Thereafter, the prevalence rises at a
rate of 2% to 3% per year. Accord-
ingly, the patient should be fol-
lowed up at monthly intervals ini-
tially and at increasing intervals once
 euthyroidism is restored, with moni-
toring of serum FT4 and thyrotrop-
in levels. Transient hypothyroid-
ism may occur during the first 6
months after 131I therapy. When hy-
pothyroidism emerges or persists for
more than 6 months after 131I
therapy, it is likely to be perma-
nent, and levothyroxine treatment
should be instituted. Other adverse
effects of therapeutic doses of 131I
for hyperthyroidism are minimal. Data
from the Swedish Cancer Registry
suggest a slight overall increase in
cancer risk but no increase in risk
for leukemia or lymphoma.14 Ac-
cordingly, since young tissue is more
sensitive to ionizing radiation, 131I
therapy is generally not considered
as the initial treatment for chil-
dren. There is no evidence for in-
creased rates of teratogenesis with
the doses of 131I used for hyperthy-
roidism.

Subtotal Thyroidectomy. Subtotal
thyroidectomy is indicated in preg-
nant patients and children who have a
major adverse reaction to propylthiouracil or methim-
zole. It is also appropriate therapy
for patients with large goiters that
extend retrosternally and lead to
compressive manifestations and
for patients with thyroid carci-
noma complicating a toxic goiter.
The patient must be restored to a
euthyroid state before surgery to
forestall postoperative thyrotoxic
 crisis. This is accomplished with
propylthiouracil or methimazole as
described earlier, and in the 7
to 10 days before surgery for
 Graves hyperthyroidism, inor-
ganic iodide is added to further
reduce thyroid vascularity. Inor-
ganic iodide should not be given
to patients with toxic nodular goi-
ter, because it may lead to exacer-
bation of hyperthyroidism. If the
patient is unable to take propyl-
thiouracil or methimazole, a
β-adrenergic receptor blocking agent
may be given in the 7 to 10
days before surgery along with
inorganic iodide. The early com-
plications of subtotal thyroidiec-
tomy, which include hypoparathy-
roidism and recurrent laryngeal
nerve damage, are rare, but per-
manent hypothyroidism will even-
tually occur in a significant per-
centage of patients. Accordingly,
the patient should be followed up
in 1 month and then at increasing
intervals thereafter, with moni-
toring of serum FT4 and thyrotropin.

Special Circumstances

Hyperthyroidism During Preg-
nancy. Hyperthyroidism that com-
pliques pregnancy may lead to in-
creased fetal loss and should
therefore be treated with antithy-
roid drugs, using the smallest dose
that maintains a euthyroid state. Pro-
pylthiouracil is usually given in pref-
erence to methimazole because of its
reported lower transplacental pas-
sage, although recent work15 does
not corroborate this difference. Since
pregnancy attenuates the course of
 Graves hyperthyroidism, probably as
a result of the increased immune tol-
erance, the antithyroid drug can of-
ten be withdrawn in the third tri-
mer but will usually have to be
reinstituted in the early postpar-
tum period. Breastfeeding can be
continued, since propylthiouracil is
poorly transferred into breast milk.
Although methimazole is readily
transferred into breast milk, a re-
cent study16 suggests that thyroid
function remains normal in breast-
fed infants of lactating mothers tak-
ing a maintenance dose of methima-
zole. If subtotal thyroidectomy is
indicated, it should be undertaken
in the middle of the second trimester.

Ophthalmopathy. Clinically overt
ophthalmopathy is seen in approxi-
mately 50% of patients with Graves
disease and runs a course that may
be independent of the hyperthy-
roid component. In patients with ac-
tive ophthalmopathy, 131I therapy
should be postponed or avoided, es-
pecially if they are cigarette smok-
ers, because it may lead to worsen-
ing of the eye disease.10,11 If, for other
reasons, 131I is the only reasonable
therapeutic option, it should be ad-
ministered as a fully ablative dose
and followed by a 3-month course of
glucocorticoid therapy, which will
forestall aggravation of the eye dis-
 ease.10

Iodine-Induced Hyperthyroidism
(Jod-Basedow Disease). Excess io-
dine has the potential to lead to hy-
perthyroidism in some patients with
multinodular goiter or other states
of relative thyroid autonomy. The io-
dine excess usually results from use
of a radiographic contrast agent or
a medication such as amiodarone, which is composed by weight of 37% iodine.17 (Amiodarone may also cause thyrotoxicosis by producing thyroiditis.) Treatment involves the use of potassium perchlorate, a drug that blocks thyroid iodide transport, and propylthiouracil or methimazole to inhibit hormone biosynthesis.

HYPOTHYROIDISM

Hypothyroidism refers to any state that results in a deficiency of thyroid hormone, including hypothalamic or pituitary disease and generalized tissue resistance to thyroid hormone, and disorders that affect the thyroid gland directly. Since the former 2 forms of hypothyroidism are rare (<5%), this article will address the management of primary thyroid failure.

Clinical Considerations

The clinical manifestations of hypothyroidism emerge insidiously, are nonspecific, and often are attributed to aging. They include a general slowing down, mental depression, modest weight gain, intolerance of cold, constipation, vague aches and pains, dryness of the skin, and brittleness of the scalp hair. As the disorder becomes more fully established, the classic features of nonpitting edema (myxedema) of the skin, periorbital edema, hoarseness, sinus bradycardia, decrease in body temperature, and delayed relaxation of the deep tendon reflexes appear. Laboratory investigation may reveal a mild anemia, increased creatine phosphokinase concentrations, and an abnormal lipid profile with increased total and low-density lipoprotein cholesterol and decreased high-density lipoprotein cholesterol concentrations. In the United States, primary thyroid failure is most often caused by chronic autoimmune thyroiditis, with or without goiter, or by prior surgical or ¹³¹I ablative therapy.

Laboratory Investigation

The laboratory hallmark of primary hypothyroidism is an increased serum thyrotropin concentration. Measurement of serum thyrotropin is the most sensitive test for detecting early thyroid failure, since an increase will antedate a decline of serum FT₄, to subnormal by many months and sometimes years (subclinical hypothyroidism). Confirmation of clinical hypothyroidism is sought in a decreased serum FT₃ level. In patients with no prior history of thyroid ablative therapy, the presence in serum of thyroperoxidase antibody will confirm chronic autoimmune thyroiditis as the cause. Because of its clinical or immunologic overlap with other autoimmune diseases, such as pernicious anemia and adrenal insufficiency, the physician should be on the alert for these in a patient with chronic autoimmune thyroiditis.18

Treatment

With the exception of certain conditions that lead to self-limited hypothyroidism, treatment of hypothyroidism will be lifelong. Levothyroxine is the drug of choice, because its conversion to L-triiodothyronine will be appropriately regulated by the tissues. The mean dose of levothyroxine sodium required to restore euthyroidism (replacement dose) in adults is approximately 1.6 μg/kg daily. Neonates and children require larger replacement doses. In patients without evidence of preexisting coronary heart disease, treatment is initiated with 50 μg/d of levothyroxine sodium and in young patients can be initiated with a full replacement dose. Serum thyrotropin, not FT₄, is used to monitor replacement. Since it takes at least 4 weeks for thyrotropin to stabilize in response to levothyroxine, dose increases should not occur more frequently. Accordingly, the patient should be followed up at 1- to 2-month intervals initially, and the dose of levothyroxine should be increased gradually until the patient is clinically euthyroid, with the serum thyrotropin level in the normal range.

In patients with preexisting angina pectoris, treatment will aggrivate angina in about one fifth and result in no change or improvement in the remainder.19 In some patients without preexisting angina, treatment will provoke the onset of angina, and some patients with coronary heart disease will experience a myocardial infarction at some time after initiation of therapy. Accordingly, for patients with angina pectoris, treatment should be initiated with 25 μg/d or less of levothyroxine sodium and the dose gradually increased at approximately 6-week intervals. Angina should be managed in the usual manner with a β-adrenergic blocking agent, but smaller-than-usual doses will be required because of its reduced clearance in the hypothyroid state. If angina cannot be controlled despite careful dosing with levothyroxine, percutaneous transluminal coronary angioplasty or coronary artery bypass grafting should be undertaken, since mortality and major morbidity do not appear to be greater than in persons in the euthyroid state.

Ideally, levothyroxine should be taken on awakening at least 30 minutes before eating, because some fiber or bran products may impair absorption.20 Moreover, if the patient is taking other medications, such as iron, antacids, sucralfate, or bile acid sequestrants, ingestion of these drugs and levothyroxine should be separated by hours.21 Finally, the dose of levothyroxine may have to be increased when its metabolic disposition is accelerated by pregnancy or by drugs that induce hepatic microsomal mixed function oxygenases, such as rifampin, phenytoin, or carbamazepine.21 Once the patient has been restored to a euthyroid state, follow-up is required only at 6- to 12-month intervals with measurement of serum thyrotropin and FT₄ levels. Overtreatment must be avoided, because thyroid hormone excess may lead to a decrease in bone mineral density in postmenopausal women and to adverse cardiac consequences.22,23

Special Circumstances: Subclinical Hypothyroidism

Subclinical hypothyroidism refers to the state in which an increased serum thyrotropin level is accompanied by a normal serum FT₄ level in an asymptomatic patient.24 Progression to overt hypothyroidism is likely
if the serum thyrotropin level exceeds 10 mIU/L or if thyroid antibodies are present in high titer. Accordingly, if either of these findings is present, a case can be made for levothyroxine replacement. Moreover, some of these patients will have an abnormal serum lipid profile that may be corrected by replacement therapy.

Accepted for publication July 12, 1999.

Reprints: Kenneth A. Woeber, MD, FRCPE, UCSF/Mount Zion, Campus Box 1640, San Francisco, CA 94143-1640.

REFERENCES


12. Tuttle RM, Patience T, Budd S. Treatment with propylthiouracil before radioactive iodine therapy is associated with a higher treatment failure rate than therapy with radioactive iodine alone in Graves’ disease. Thyroid. 1995;5:243-247.


